Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12002611 | 0.93 | IDO1 (0.52) | IDO1MAOBAPPMEN1RAB9A | |
| SCHEMBL134443 | 0.86 | IDO1 (0.46) | IDO1MAOBAPPLMNATSHR | |
| SCHEMBL3106528 | 0.81 | IDO1 (0.50) | IDO1MAOBAPPMEN1RAB9A | |
| SCHEMBL4661955 | 0.81 | IDO1 (0.50) | IDO1MAOBAPPMEN1RAB9A | |
| SCHEMBL8424756 | 0.80 | IDO1 (0.54) | IDO1MAOBAPPMEN1RAB9A | |
| SCHEMBL15602862 | 0.80 | IDO1 (0.48) | IDO1MAOBAPPMEN1RAB9A | |
| SCHEMBL4371209 | 0.79 | TRPA1 (0.43) | IDO1MAOBAPPLMNATSHR | |
| SCHEMBL3139555 | 0.78 | PTPN1 (0.48) | IDO1MAOBMEN1RAB9AKMT2A | |
| SCHEMBL9679767 | 0.78 | TSHR (0.52) | IDO1APPLMNATSHRL3MBTL1 | |
| SCHEMBL649020 | 0.78 | IDO1 (0.64) | IDO1MAOBAPPRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685251-B | Direct cross-coupling reaction method of diaryl sulfoxide and aryl bromide | 南京工业大学 | 2022-12-27 | — | — | CN | claimed |
| CN-114685251-A | Direct cross-coupling reaction method of diaryl sulfoxide and aryl bromide | 南京工业大学 | 2022-07-01 | — | — | CN | claimed |
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | claimed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | claimed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4637754-A2 | SELECTIVE BET INHIBITORS AND USES THEREOF | Tay Therapeutics Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| US-12384860-B2 | Hybrid supported metallocene catalyst and process for preparing polyethylene copolymer using the same | LG CHEM, LTD. (KR) | 2025-08-12 | — | — | US | disclosed |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4501912-A1 | NOVEL HETEROCYCLIC COMPOUND | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-4791139-A | Diphenyl ether derivatives and their use as insecticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-12-13 | — | — | US | disclosed |
| CN-87102455-A | Diphenyl ether derivatives pesticide compound | — | 1988-01-27 | — | — | CN | disclosed |
| EP-0240121-A2 | Diphenyl ether derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-10-07 | — | — | EP | disclosed |
| EP-0211561-A1 | Insecticidal ethers | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-02-25 | — | — | EP | disclosed |
| CN-86105891-A | Desinsection ether | — | 1987-02-25 | — | — | CN | disclosed |
| US-4591648-A | Histidine protection | NATIONAL RESEARCH DEVELOPMENT CORP. (GB) | 1986-05-27 | — | — | US | disclosed |
| US-4496745-A | Epoxycarbacyclin derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1985-01-29 | — | — | US | disclosed |
| EP-0061933-A2 | Histidine protection | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | CKS1B, CSNK1A1, CKS2 | IDO1 1592/4885MAOB 4157/4885APP 3767/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | IDO1 3364/4885MAOB 2567/4885APP 3148/4885 |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | IDO1 3591/4885MAOB 593/4885APP 544/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | IDO1 638/4885MAOB 120/4885APP 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.